Efficacy of etanercept in psoriatic patients previously treated with infliximab

Dermatology

Volumn 216, Issue 4, 2008, Pages 312-316

  Pitarch, Gerard ^a,b   Sánchez Carazo, José Luís ^a   Mahiques, Laura ^a   Oliver, Vicente ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b HOSPITAL GENERAL DE CASTELLÓN   (Spain)

Author keywords

Etanercept; Infliximab; Psoriasis; Switching

Indexed keywords

CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DISEASE SEVERITY; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; MALE; MONOTHERAPY; PRIORITY JOURNAL; PSORIASIS; TREATMENT RESPONSE;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 43049086693     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000113943     Document Type: Article

References (19)

1. Boehncke WH: Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus. J Eur Acad Dermatol Venereol 2006;20:988-998.
2. Ang HT, Helfgott S: Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 2003;30:2315-2318.
3. Hansen KE, Hildebrand JP, Genovese MC, et al: The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004;31:1098-1102.
4. Haraoui B: Is there a rationale for switching from one antitumor necrosis factor agent to another? (editorial). J Rheumatol 2004;31:1021-1022.
5. Sieper J, van den Brande J: Diverse effects of infliximab and etanercept on T lymphocytes. Semin Arthritis Rheum 2005;34(suppl 1):23-27.
6. Delaunay C, Farrenq V, Marini-Portugal A, et al: Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol 2005;32:2183-2185.
7. Cantina F, Niccoli L, Benucci M, et al: Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Arthritis Rheum 2006;55:812-816.
8. Barde C, Thielen AM, Saurat J-H: Infliximab then efalizumab, the 'hit and run' approach does not work. Dermatology 2008;216:171-172.
9. SanmartíR, Gómez-Puerta JA, Rodríguez-Cros JR, et al: Etanercept en pacientes con artritis reumatoide y escasa respuesta terapéutica a infliximab. Med Clin (Barc) 2004;122:321-324.
10. Van Vollenhoven R, Harju A, Brannemark S, Klareskog L: Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann Rheum Dis 2003;62:1195-1198.
11. Buch MH, Seto Y, Bingham SJ, et al: C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis. Arthritis Rheum 2005;52:42-48.
12. Favalli EG, Arreghini M, Arnoldi C, et al: Anti-tumor necrosis factor α switching in rheumatoid arthritis and juvenile chronic arthritis. Arthritis Rheum 2004;51:301-302.
13. Brocq O, Plubel Y, Breuil V, et al: Switch étanercept-infliximab dans la polyarthrite rhumatoïde. Presse Med 2002;31:1836-1839.
14. Haraoui B, Keystone EC, Thorne JC, et al: Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004;31:2356-2359.
15. Heenen M, Simonart T: Biological agents and psoriatic epidermis: what are we ultimately targeting? Dermatology 2006;212:321-323.
16. Haraoui B: Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum 2004;34(suppl 1):7-11.
17. Van Vollenhoven RF: Switching between biological agents. Clin Exp Rheumatol 2004;22(suppl 35):S115-S121.
18. Nestorov I: Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arhritis Rheum 2004;34(suppl 1):12-18.
19. Baert F, Noman M, Vermeire S, et al: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-608.